滤泡性淋巴瘤长期生存患者的治疗影响：一项西班牙淋巴瘤肿瘤学组登记研究。

Impact of treatment in long-term survival patients with follicular lymphoma: A Spanish Lymphoma Oncology Group registry.

作者信息

Provencio Mariano, Sabín Pilar, Gomez-Codina Jose, Torrente Maria, Calvo Virginia, Llanos Marta, Gumá Josep, Quero Cristina, Blasco Ana, Cruz Miguel Angel, Aguiar David, García-Arroyo Francisco, Lavernia Javier, Martinez Natividad, Morales Manuel, Saez-Cusi Alvaro, Rodriguez Delvys, de la Cruz Luis, Sanchez Jose Javier, Rueda Antonio

机构信息

Department of Medical Oncology, Hospital Universitario Puerta de Hierro-Majadahonda, Madrid, Spain.

Department of Medical Oncology, Hospital Universitario Gregorio Marañón, Madrid, Spain.

出版信息

PLoS One. 2017 May 11;12(5):e0177204. doi: 10.1371/journal.pone.0177204. eCollection 2017.

DOI:10.1371/journal.pone.0177204

PMID:28493986

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5426713/

Abstract

BACKGROUND

Follicular lymphoma is the second most common non-Hodgkin lymphoma in the United States and Europe. However, most of the prospective randomized studies have very little follow-up compared to the long natural history of the disease. The primary aim of this study was to investigate the long-term survival of our series of patients with follicular lymphoma.

PATIENTS AND METHODS

A total of 1074 patients with newly diagnosed FL were enrolled. Patients diagnosed were prospectively enrolled from 1980 to 2013.

RESULTS

Median follow-up was 54.9 months and median overall survival is over 20 years in our series. We analyzed the patients who are still alive beyond 10 years from diagnosis in order to fully assess the prognostic factors that condition this group. Out of 166 patients who are still alive after more than 10 years of follow-up, 118 of them (73%) are free of evident clinical disease. Variables significantly associated with survival at 10 years were stage < II (p <0.03), age < 60 years (p <0.0001), low FLIPI (p <0.002), normal β2 microglobulin (p <0.005), no B symptoms upon diagnosis (p <0.02), Performance Status 0-1 (p <0.03) and treatment with anthracyclines and rituximab (p <0.001), or rituximab (p <0.0001).

CONCLUSIONS

A longer follow-up and a large series demonstrated a substantial population of patients with follicular lymphoma free of disease for more than 10 years.

摘要

背景

滤泡性淋巴瘤是美国和欧洲第二常见的非霍奇金淋巴瘤。然而，与该疾病漫长的自然病程相比，大多数前瞻性随机研究的随访时间都很短。本研究的主要目的是调查我们系列滤泡性淋巴瘤患者的长期生存情况。

患者与方法

共纳入1074例新诊断的滤泡性淋巴瘤患者。确诊患者于1980年至2013年前瞻性入组。

结果

在我们的系列研究中，中位随访时间为54.9个月，中位总生存期超过20年。我们分析了诊断后存活超过10年的患者，以全面评估影响该组患者预后的因素。在随访超过10年仍存活的166例患者中，118例（73%）无明显临床疾病。与10年生存率显著相关的变量包括分期<II期（p<0.03）、年龄<60岁（p<0.0001）、滤泡性淋巴瘤国际预后指数（FLIPI）低（p<0.002）、β2微球蛋白正常（p<0.005）、诊断时无B症状（p<0.02）、体能状态0-1级（p<0.03）以及接受蒽环类药物和利妥昔单抗治疗（p<0.001）或利妥昔单抗单药治疗（p<0.0001）。